Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data

Jann N. Sarkaria; Leland S. Hu; Ian F. Parney; Deanna H. Pafundi; Debra H. Brinkmann; Nadia N. Laack; Caterina Giannini; Terence C. Burns; Sani H. Kizilbash; Janice K. Laramy; Kristin R. Swanson; Timothy J. Kaufmann; Paul D. Brown; Nathalie Y.R. Agar; Evanthia Galanis; Jan C. Buckner; William F. Elmquist

doi:10.1093/neuonc/nox175

Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data

Jann N. Sarkaria, Leland S. Hu, Ian F. Parney, Deanna H. Pafundi, Debra H. Brinkmann, Nadia N. Laack, Caterina Giannini, Terence C. Burns, Sani H. Kizilbash, Janice K. Laramy, Kristin R. Swanson, Timothy J. Kaufmann, Paul D. Brown, Nathalie Y.R. Agar, Evanthia Galanis, Jan C. Buckner, William F. Elmquist

Pharmaceutics

Research output: Contribution to journal › Article › peer-review

415 Scopus citations

Abstract

The blood-brain barrier (BBB) excludes the vast majority of cancer therapeutics from normal brain. However, the importance of the BBB in limiting drug delivery and efficacy is controversial in high-grade brain tumors, such as glioblastoma (GBM). The accumulation of normally brain impenetrant radiographic contrast material in essentially all GBM has popularized a belief that the BBB is uniformly disrupted in all GBM patients so that consideration of drug distribution across the BBB is not relevant in designing therapies for GBM. However, contrary to this view, overwhelming clinical evidence demonstrates that there is also a clinically significant tumor burden with an intact BBB in all GBM, and there is little doubt that drugs with poor BBB permeability do not provide therapeutically effective drug exposures to this fraction of tumor cells. This review provides an overview of the clinical literature to support a central hypothesis: that all GBM patients have tumor regions with an intact BBB, and cure for GBM will only be possible if these regions of tumor are adequately treated.

Original language	English (US)
Pages (from-to)	184-191
Number of pages	8
Journal	Neuro-Oncology
Volume	20
Issue number	2
DOIs	https://doi.org/10.1093/neuonc/nox175
State	Published - Jan 22 2018

Bibliographical note

Funding Information:
This work was supported by the MIT/Mayo Physical Sciences Center for Drug Distribution and Efficacy in Brain Tumors (U54CA210180), the Mayo Clinic SPORE in Brain Cancer (P50CA108961), and RO1NS077921. We gratefully acknowledge the support of the MIT/Mayo Physical Sciences Center for Drug Distribution and Efficacy in Brain Tumors (U54CA210180), the James S. McDonnell Foundation, the Ivy Foundation, the Mayo Clinic SPORE in Brain Cancer (P50CA108961) and the NIH (RO1NS077921, R01 NS060752, R01 CA164371, U54 CA210180, U54 CA143970, U54 CA193489, U01CA220378).

Publisher Copyright:
© The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.

Keywords

blood brain barrier
drug therapy
glioblastoma
magnetic resonance imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1093/neuonc/nox175

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777482

OpenUrl availability

Full text

Cite this

Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., Giannini, C., Burns, T. C., Kizilbash, S. H., Laramy, J. K., Swanson, K. R., Kaufmann, T. J., Brown, P. D., Agar, N. Y. R., Galanis, E., Buckner, J. C., & Elmquist, W. F. (2018). Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-Oncology, 20(2), 184-191. https://doi.org/10.1093/neuonc/nox175

Sarkaria, JN, Hu, LS, Parney, IF, Pafundi, DH, Brinkmann, DH, Laack, NN, Giannini, C, Burns, TC, Kizilbash, SH, Laramy, JK, Swanson, KR, Kaufmann, TJ, Brown, PD, Agar, NYR, Galanis, E, Buckner, JC & Elmquist, WF 2018, 'Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data', Neuro-Oncology, vol. 20, no. 2, pp. 184-191. https://doi.org/10.1093/neuonc/nox175

@article{cbbeacced1544ea18a94e45f4bf4c0a2,

title = "Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data",

abstract = "The blood-brain barrier (BBB) excludes the vast majority of cancer therapeutics from normal brain. However, the importance of the BBB in limiting drug delivery and efficacy is controversial in high-grade brain tumors, such as glioblastoma (GBM). The accumulation of normally brain impenetrant radiographic contrast material in essentially all GBM has popularized a belief that the BBB is uniformly disrupted in all GBM patients so that consideration of drug distribution across the BBB is not relevant in designing therapies for GBM. However, contrary to this view, overwhelming clinical evidence demonstrates that there is also a clinically significant tumor burden with an intact BBB in all GBM, and there is little doubt that drugs with poor BBB permeability do not provide therapeutically effective drug exposures to this fraction of tumor cells. This review provides an overview of the clinical literature to support a central hypothesis: that all GBM patients have tumor regions with an intact BBB, and cure for GBM will only be possible if these regions of tumor are adequately treated.",

keywords = "blood brain barrier, drug therapy, glioblastoma, magnetic resonance imaging",

author = "Sarkaria, {Jann N.} and Hu, {Leland S.} and Parney, {Ian F.} and Pafundi, {Deanna H.} and Brinkmann, {Debra H.} and Laack, {Nadia N.} and Caterina Giannini and Burns, {Terence C.} and Kizilbash, {Sani H.} and Laramy, {Janice K.} and Swanson, {Kristin R.} and Kaufmann, {Timothy J.} and Brown, {Paul D.} and Agar, {Nathalie Y.R.} and Evanthia Galanis and Buckner, {Jan C.} and Elmquist, {William F.}",

note = "Funding Information: This work was supported by the MIT/Mayo Physical Sciences Center for Drug Distribution and Efficacy in Brain Tumors (U54CA210180), the Mayo Clinic SPORE in Brain Cancer (P50CA108961), and RO1NS077921. We gratefully acknowledge the support of the MIT/Mayo Physical Sciences Center for Drug Distribution and Efficacy in Brain Tumors (U54CA210180), the James S. McDonnell Foundation, the Ivy Foundation, the Mayo Clinic SPORE in Brain Cancer (P50CA108961) and the NIH (RO1NS077921, R01 NS060752, R01 CA164371, U54 CA210180, U54 CA143970, U54 CA193489, U01CA220378). Publisher Copyright: {\textcopyright} The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.",

year = "2018",

month = jan,

day = "22",

doi = "10.1093/neuonc/nox175",

language = "English (US)",

volume = "20",

pages = "184--191",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data

AU - Sarkaria, Jann N.

AU - Hu, Leland S.

AU - Parney, Ian F.

AU - Pafundi, Deanna H.

AU - Brinkmann, Debra H.

AU - Laack, Nadia N.

AU - Giannini, Caterina

AU - Burns, Terence C.

AU - Kizilbash, Sani H.

AU - Laramy, Janice K.

AU - Swanson, Kristin R.

AU - Kaufmann, Timothy J.

AU - Brown, Paul D.

AU - Agar, Nathalie Y.R.

AU - Galanis, Evanthia

AU - Buckner, Jan C.

AU - Elmquist, William F.

N1 - Funding Information: This work was supported by the MIT/Mayo Physical Sciences Center for Drug Distribution and Efficacy in Brain Tumors (U54CA210180), the Mayo Clinic SPORE in Brain Cancer (P50CA108961), and RO1NS077921. We gratefully acknowledge the support of the MIT/Mayo Physical Sciences Center for Drug Distribution and Efficacy in Brain Tumors (U54CA210180), the James S. McDonnell Foundation, the Ivy Foundation, the Mayo Clinic SPORE in Brain Cancer (P50CA108961) and the NIH (RO1NS077921, R01 NS060752, R01 CA164371, U54 CA210180, U54 CA143970, U54 CA193489, U01CA220378). Publisher Copyright: © The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.

PY - 2018/1/22

Y1 - 2018/1/22

N2 - The blood-brain barrier (BBB) excludes the vast majority of cancer therapeutics from normal brain. However, the importance of the BBB in limiting drug delivery and efficacy is controversial in high-grade brain tumors, such as glioblastoma (GBM). The accumulation of normally brain impenetrant radiographic contrast material in essentially all GBM has popularized a belief that the BBB is uniformly disrupted in all GBM patients so that consideration of drug distribution across the BBB is not relevant in designing therapies for GBM. However, contrary to this view, overwhelming clinical evidence demonstrates that there is also a clinically significant tumor burden with an intact BBB in all GBM, and there is little doubt that drugs with poor BBB permeability do not provide therapeutically effective drug exposures to this fraction of tumor cells. This review provides an overview of the clinical literature to support a central hypothesis: that all GBM patients have tumor regions with an intact BBB, and cure for GBM will only be possible if these regions of tumor are adequately treated.

AB - The blood-brain barrier (BBB) excludes the vast majority of cancer therapeutics from normal brain. However, the importance of the BBB in limiting drug delivery and efficacy is controversial in high-grade brain tumors, such as glioblastoma (GBM). The accumulation of normally brain impenetrant radiographic contrast material in essentially all GBM has popularized a belief that the BBB is uniformly disrupted in all GBM patients so that consideration of drug distribution across the BBB is not relevant in designing therapies for GBM. However, contrary to this view, overwhelming clinical evidence demonstrates that there is also a clinically significant tumor burden with an intact BBB in all GBM, and there is little doubt that drugs with poor BBB permeability do not provide therapeutically effective drug exposures to this fraction of tumor cells. This review provides an overview of the clinical literature to support a central hypothesis: that all GBM patients have tumor regions with an intact BBB, and cure for GBM will only be possible if these regions of tumor are adequately treated.

KW - blood brain barrier

KW - drug therapy

KW - glioblastoma

KW - magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=85041222514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041222514&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nox175

DO - 10.1093/neuonc/nox175

M3 - Article

C2 - 29016900

AN - SCOPUS:85041222514

SN - 1522-8517

VL - 20

SP - 184

EP - 191

JO - Neuro-Oncology

JF - Neuro-Oncology

IS - 2

ER -

Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this